| 证券代码:300601 | | --- | | 债券代码:123119 | 证券代码：300601 证券简称：康泰生物 公告编号：2025-081 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更、否决议案的情况； 2、本次股东会未涉及变更以往股东会决议的情况； 3、本次股东会采取现场投票与网络投票相结合的方式召开。 一、会议召开情况 1、会议召开时间： （1）现场会议时间：2025 年 11 月 18 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 18 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2025 年 11 月 18 日 9:15-15:00。 2、会议召开地点：深圳市南山区粤海街道科技园社区科发路 222 号康泰集 团大厦公司会议室。 3、会议召开方式：现场 ...

Group 1 - The vaccine sector experienced a significant rise, with Gendik hitting the daily limit increase [1] - Other companies such as Watson Bio, Zhifei Bio, Kangtai Bio, Baike Bio, and Kangle Weishi also saw gains [1]

Group 1 - Huayang Intelligent's shareholder, Fosun Weiying, plans to reduce its stake by up to 285.42 million shares, representing no more than 5% of the company [1] - Kangtai Biological's controlling shareholder's concerted actor, Du Xinglian, intends to reduce its stake by up to 272.4 million shares, which is no more than 0.24% of the total share capital [2] - Mindray Medical has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [4] Group 2 - Junpu Intelligent's chairman, Liu Yuan, resigned for personal reasons, and Wang Jianfeng was elected as the new chairman [6] - Mingchen Health's actual controller and executives plan to collectively reduce their stake by up to 8.61 million shares, accounting for 3.27% of the total share capital [7] - Zhongheng Design's directors and executives plan to reduce their stake by up to 151.57 million shares, representing no more than 0.55% of the total share capital [9] Group 3 - ST Erya and its actual controller, Zheng Jiping, are still under investigation by the China Securities Regulatory Commission [10] - Qicai Chemical's shareholder, Beijing Fengyan, plans to reduce its stake by up to 399.12 million shares, accounting for 0.98% of the total share capital [11] - Aier Eye Hospital plans to distribute a cash dividend of 0.8 yuan per 10 shares to all shareholders, totaling approximately 744 million yuan [12] Group 4 - Meiri Interactive's actual controller's concerted actor plans to reduce its stake by up to 394.74 million shares, which is 1% of the total share capital [13] - Maipu Medical's pre-IPO shareholder plans to reduce its stake by up to 67.05 million shares, representing no more than 1% of the total share capital [15] - Qinchuan Machine Tool's subsidiary plans to increase its registered capital from 50 million yuan to 200 million yuan, introducing new investors [17] Group 5 - Guiyang Bank's proposed director, Yu Rui, has resigned due to work reasons [19] - Guiyang Bank plans to acquire Xifeng Development Village Bank and establish a branch [20] - Aojing Medical's directors and executives plan to collectively reduce their stake by up to 25.28 million shares, accounting for no more than 0.19% of the total share capital [21] Group 6 - Zhongji Xuchuang intends to issue H-shares and list on the Hong Kong Stock Exchange [22] - ST Huatuo's stock will have its risk warning lifted, changing its name to Shiji Huatuo [25] - *ST Gaohong's stock has been delisted from the Shenzhen Stock Exchange [27] Group 7 - Tianwo Technology plans to publicly transfer a 7.12% stake in Qinghai Haihe Railway Transportation Co., with an assessed value of approximately 8.54 million yuan [28] - Xingye Technology's major shareholder plans to reduce its stake by up to 886.65 million shares, representing no more than 3% of the total share capital [29] - Jiangnan Chemical has successfully acquired 100% equity of Chongqing Shun'an Explosive Materials Co., with a transfer base price of 1 billion yuan [31]

Core Points - The company announced that its controlling shareholder, Du Xinglian, plans to reduce her shareholding by up to 2,724,048 shares, which represents 0.24% of the total share capital [1] - The reduction will take place within three months after the announcement, excluding periods when reductions are legally prohibited [1] - The implementation of this reduction plan will not affect the company's governance structure or ongoing operations, nor will it lead to a change in control of the company [1]

Summary of Key Points Core Viewpoint - On November 10, several A-share listed companies disclosed their shareholding changes, with some announcing share buybacks while others reported share reductions by major shareholders [1]. Group 1: Share Buybacks - Hangcai Co. proposed to use 50 million to 100 million yuan of surplus funds for share repurchase [2]. - Sunong Bank executives plan to increase their holdings by no less than 1.8 million yuan in A-shares within six months [2]. - Jiangsu Cable's controlling shareholder received loan support for increasing A-share holdings [2]. Group 2: Share Reductions - A total of 25 A-share listed companies announced share reductions, including: - Aojing Medical plans to reduce no more than 0.19% of its shares by directors and executives [2]. - Maipu Medical's shareholder Guoshou Chengda intends to reduce no more than 1% of its shares [2]. - Shoulv Hotel's Ctrip Shanghai reduced 25.206 million shares on November 10 [2]. - Mingchen Health's controlling shareholder plans to reduce no more than 3% of the total share capital [2]. - Meiri Interactive's shareholder "I Got a Push" intends to reduce no more than 1% of its shares [2]. - Qicai Chemical's shareholder Beijing Fengyan plans to reduce no more than 0.98% of its shares [2]. - Other companies with planned reductions include Zhongheng Design, Xin Kaipu, Lianying Laser, Hongxin Electronics, and others, with reductions ranging from 0.07% to 5% [2].

Core Viewpoint - The controlling shareholder and actual controller's concerted action party, Ms. Du Xinglian, plans to reduce her shareholding in Kangtai Biological (300601.SZ) by up to 2.724 million shares, which represents 0.24% of the company's total share capital, within three months after the announcement [1] Summary by Relevant Sections - Shareholding Details - Ms. Du Xinglian holds 2.724 million shares, accounting for 0.24% of the total share capital of the company [1] - Reduction Plan - The planned reduction will occur within three months after the announcement, excluding periods where reduction is prohibited by laws and regulations [1] - The reduction will be executed through centralized bidding or block trading methods, with a maximum limit of 2.724 million shares [1]

Core Viewpoint - Kangtai Biological (300601.SZ) announced that its controlling shareholder and actual controller's concerted action person, Ms. Du Xinglian, plans to reduce her shareholding in the company by up to 2.724 million shares, representing 0.24% of the total share capital, within three months after a fifteen trading day period following the announcement [1] Summary by Categories Shareholding Reduction - Ms. Du Xinglian holds 2.724 million shares, accounting for 0.24% of the company's total share capital [1] - The planned reduction will occur through centralized bidding or block trading methods [1] - The reduction is subject to legal regulations and normative documents that restrict shareholding reductions [1]

Core Viewpoint - Kangtai Biological (300601.SZ) announced that its controlling shareholder and actual controller's concerted action person, Ms. Du Xinglian, plans to reduce her shareholding by up to 2,724,048 shares, representing 0.24% of the total share capital, within three months after the announcement [1] Group 1 - Ms. Du Xinglian currently holds 2,724,048 shares, accounting for 0.24% of the company's total share capital [1] - The planned reduction will occur through centralized bidding or block trading methods [1] - The implementation of this reduction plan will not affect the company's governance structure or ongoing operations, nor will it lead to a change in control of the company [1]

Group 1 - The core point of the news is that Kangtai Biological (SZ 300601) announced a share reduction plan by its major shareholder, which will not affect the company's governance structure or control [1] - The major shareholder, Ms. Du Xinglian, plans to reduce her holdings by up to approximately 2.72 million shares, representing 0.24% of the total share capital, within three months after the announcement [1] - For the year 2024, Kangtai Biological's revenue composition is projected to be 98.31% from biological products and 1.69% from other business income [1] Group 2 - As of the report, Kangtai Biological has a market capitalization of 19.5 billion yuan [2]

Core Viewpoint - The company announced that its controlling shareholder, Du Xinglian, plans to reduce his holdings by up to 2.724 million shares, representing 0.24% of the total share capital, due to personal financial needs [1] Summary by Relevant Sections - **Shareholder Information** - Du Xinglian holds 2.724 million shares, accounting for 0.24% of the company's total share capital [1] - **Reduction Plan** - The planned reduction will occur within three months after a fifteen trading day period following the announcement [1] - The shares will be sold through centralized bidding or block trading [1] - **Source of Shares** - The shares being reduced were acquired prior to the company's initial public offering [1]